Physician profile
Allan Chen
NPI 1043473531
$4,003.31
in general payments reported to CMS, 2019-2025
14 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $340 · 2022: $601 · 2023: $363 · 2024: $1,135 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226 · Travel and Lodging: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.66 |
| Travel and Lodging | $717.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,206.20 | 2019-2024 | Mitraclip |
| Heartflow, INC. | $1,064.95 | 2022-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $426.84 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $266.69 | 2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $220.09 | 2023 | Pascal |
| Boston Scientific Corporation | $201.21 | 2022-2025 | General - Therapies |
| Impulse Dynamics (USA) INC. | $164.04 | 2022 | |
| Medtronic, INC. | $96.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.88 | 2022 | |
| Biosense Webster, INC. | $85.91 | 2025 | Nuvision Ice Catheter |
| Amgen INC. | $73.15 | 2019-2025 | Repatha, Repatha |
| Ethicon US, LLC | $47.79 | 2022 | |
| Pfizer INC. | $35.21 | 2024-2025 | |
| Scpharmaceuticals INC. | $19.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.